Unveiling the Potential Drug Target and Biomarker TMA7: Coiled-Coil Domain-Containing Protein 72

Target Name: TMA7

NCBI ID: G51372

TMA7

Unveiling the Potential Drug Target and Biomarker TMA7: Coiled-Coil Domain-Containing Protein 72

Protein 72 (TMA7) is a highly conserved cDNA-encoded protein that is expressed in various tissues and organs, including brain, heart, skeletal muscles, and the liver. Its protein structure is unique, as it is a member of the superfamily of ATP-binding proteins (APBPs) and is known to have coiled-coil domains. The functional role of TMA7 in various biological processes is not well understood, but its potential involvement in diseases such as cancer, neurodegenerative disorders, and autoimmune diseases makes it an attractive target for research and development of new treatments.

Potential Drug Target

TMA7 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the most significant factors that make TMA7 an attractive drug target is its ability to interact with various molecules, including nucleotides, ion channels, and proteins. This interaction between TMA7 and these molecules suggests that it may play a role in regulating various cellular processes, including DNA replication, gene expression, and signaling pathways.

In addition to its potential role in cellular processes, TMA7's structure also makes it a unique drug target. The coiled-coil domains of TMA7 are known to be involved in the protein's stability and functions, and these domains may be potential drug targets. Studies have shown that TMA7's coiled-coil domains are involved in its stability and that alterations in these domains can affect the protein's stability and function. This suggests that targeting TMA7's coiled-coil domains may be a promising strategy for developing new treatments.

Biomarker

TMA7 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The unique structure of TMA7 and its involvement in various cellular processes make it an attractive candidate for use as a biomarker.

In cancer, TMA7 has been shown to be involved in various cellular processes that are associated with cancer progression, including cell division, angiogenesis, and immune evasion. TMA7 has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This suggests that TMA7 may be a useful biomarker for the development of new cancer therapies.

In neurodegenerative disorders, TMA7 has been shown to be involved in the regulation of cellular processes that are associated with neurodegeneration, including axon growth and synaptic plasticity. The unique structure of TMA7 and its involvement in these processes make it an attractive candidate for use as a biomarker for neurodegenerative disorders.

In autoimmune diseases, TMA7 has been shown to be involved in the regulation of cellular processes that are associated with autoimmune diseases, including inflammation and immune evasion. The unique structure of TMA7 and its involvement in these processes make it an attractive candidate for use as a biomarker for autoimmune diseases.

Conclusion

TMA7 is a unique protein that has been identified as a potential drug target and biomarker. Its unique structure and its involvement in various cellular processes make it an attractive candidate for research and development of new treatments. Further studies are needed to fully understand the functional role of TMA7 in various biological processes and to determine its potential as a drug target and biomarker.

Protein Name: Translation Machinery Associated 7 Homolog

The "TMA7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMA7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets